Medical Condition News

RSS

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

Ultrasound settings can change beat frequency of cardiac cells

Ultrasound—the technology used for sonograms and examining the heart—can increase the rate at which heart cells beat, researchers from Drexel University report.

24 Apr 2015

Study: Long-term exposure to air pollution can damage brain structures, impair cognitive function

Air pollution, even at moderate levels, has long been recognized as a factor in raising the risk of stroke. A new study led by scientists from Beth Israel Deaconess Medical Center and Boston University School of Medicine suggests that long-term exposure can cause damage to brain structures and impair cognitive function in middle-aged and older adults.

24 Apr 2015

Fruit fly study shows that extra sleep helps the brain overcome neurological defects

Many studies have linked more sleep to better memory, but new research in fruit flies demonstrates that extra sleep helps the brain overcome catastrophic neurological defects that otherwise would block memory formation, report scientists at Washington University School of Medicine in St. Louis.

24 Apr 2015

Oncologists publish review of advanced clinical treatments for pancreatic cancer

The oncologists Manuel Hidalgo, Director of the Clinical Research Programme of the Spanish National Cancer Research Centre, and Ignacio Garrido-Laguna, member of the Experimental Therapeutics Program at Huntsman Cancer Institute of the University of Utah (USA), have recently published a review of state-of-the-art clinical treatments for pancreatic cancer -- including the most current therapies and innovative research -- in the prestigious scientific journal Nature Reviews Clinical Oncology.

24 Apr 2015

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases.

24 Apr 2015

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

A new study led by University of Toronto researcher Dr. David Lam has discovered the trigger behind the most severe forms of cancer pain. Released in top journal Pain this month, the study points to TMPRSS2 as the culprit: a gene that is also responsible for some of the most aggressive forms of androgen-fuelled cancers.

24 Apr 2015

UTMB study highlights current use of oxygen therapy in patents with COPD

A new study about the use of oxygen to treat chronic obstructive pulmonary disease from The University of Texas Medical Branch at Galveston found that the majority of patients receiving oxygen therapy were low-income, non-Hispanic white females about 75 years old with two or more other health conditions.

24 Apr 2015

Scientists identify possible new genes that could change benign skin growths into fatal melanomas

A Houston Methodist-led team of international scientists has identified hundreds of possible new genes in mice that could transform benign skin growths into deadly melanomas.

24 Apr 2015

Bacterial imbalance in the gut can lead to inflammation similar to Crohn's disease

Crohn's disease is one of a family of chronic inflammatory bowel diseases (IBD). While it has already been proven to have genetic causes, scientists have now shown that the presence of certain intestinal bacteria also plays a role.

24 Apr 2015

Johns Hopkins study finds that nearly one-quarter of ICU survivors experience PTSD

Post-traumatic stress disorder is often thought of as a symptom of warfare, major catastrophes and assault. It’s rarely considered in patients who survive a critical illness and stay in the intensive care unit (ICU). However, in a recent Johns Hopkins study, researchers found that nearly one-quarter of ICU survivors suffer from PTSD.

24 Apr 2015

First CE marked FGF23 ELISA assay launched at Biomedica Immunoassays

The biomarker specialists at Biomedica Immunoassays, announced the launch of the first CE marked FGF23 (C-terminal) ELISA assay which specifically detects both intact and C-terminal fragments of FGF23 in human serum and plasma. The FGF23 ELISA assay complements the existing Biomedica assays directed against chronic kidney disease - mineral and bone disorder (CKD-MBD) in a growing collection.

24 Apr 2015

New study finds high mortality risks from alcohol and drug abuse among ex-prisoners

Alcohol and drug misuse are responsible for around a third of all deaths in former male prisoners and half in female ex-prisoners, a new study of almost 48000 ex-prisoners published in The Lancet Psychiatry journal has found. Moreover, the research shows that a substantial proportion of these deaths are from preventable causes, including accidents and suicide (42% in men and 70% in women).

24 Apr 2015

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).

24 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo).

24 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

24 Apr 2015

Cardiff scientists make breakthrough asthma discovery

Cardiff University scientists have for the first time identified the potential root cause of asthma and an existing drug that offers a new treatment.

24 Apr 2015

New research shows that serious life events in childhood can increase type 1 diabetes risk

New research from Sweden published in Diabetologia (the journal of the European Association for the Study of Diabetes) shows that serious life events (SLEs) in childhood, such as death or illness in the family, divorce/separation, a new child or adult in the family, and conflicts in the family, can triple the risk of subsequently developing type 1 diabetes (T1D).

23 Apr 2015

VTT develops easy-to-use ketosis test that can benefit diabetics and dieters

VTT has developed a quick, easy-to-use ketosis test for consumers that can detect acetone on exhaled breath. The test will benefit diabetics and dieters in particular, but it can easily be adapted to other uses as well, such as the detection of the air pollutants formaldehyde or acetaldehyde. VTT is now seeking a partner to commercialise the product.

23 Apr 2015

Study show that silymarin may be a useful treatment for NASH

Results from a double-blind, placebo-controlled study of silymarin, which is derived from the milk thistle plant, have shown that this herbal remedy may be a useful treatment option for non-alcoholic steatohepatitis (NASH).

23 Apr 2015

Medical Condition News

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Ultrasound settings can change beat frequency of cardiac cells

Study: Long-term exposure to air pollution can damage brain structures, impair cognitive function

Fruit fly study shows that extra sleep helps the brain overcome neurological defects

Oncologists publish review of advanced clinical treatments for pancreatic cancer

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

Study points to TMPRSS2 gene as culprit for aggressive forms of androgen-fuelled cancers

UTMB study highlights current use of oxygen therapy in patents with COPD

Scientists identify possible new genes that could change benign skin growths into fatal melanomas

Bacterial imbalance in the gut can lead to inflammation similar to Crohn's disease

Johns Hopkins study finds that nearly one-quarter of ICU survivors experience PTSD

First CE marked FGF23 ELISA assay launched at Biomedica Immunoassays

New study finds high mortality risks from alcohol and drug abuse among ex-prisoners

Alnylam announces clinical data from patisiran Phase 2 OLE study for treatment of patients with FAP

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Cardiff scientists make breakthrough asthma discovery

New research shows that serious life events in childhood can increase type 1 diabetes risk

VTT develops easy-to-use ketosis test that can benefit diabetics and dieters

Study show that silymarin may be a useful treatment for NASH

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News